Diagnostic Value of Fecal Calprotectin as a Screening Biomarker for Gastrointestinal Malignancies

Abstract

Background: Calprotectin in feces seems to be a more sensitive marker for gastrointestinal (GI) cancers than fecal occult blood, but its specificity may be too low for screening average risk populations. This study aims at evaluating the diagnostic value of fecal calprotectin as a screening biomarker for GI malignancies. Materials and Methods: In a case-control study, 100 patients with GI malignancies (50 patients with colorectal cancer and 50 patients with gastric cancer) and 50 controls were recruited in Tabriz 3) in gastric cancer, colorectal cancer and control group, respectively, the differences being significant (p<0.001) and remaining after adjustment for age. The optimal cut-off point for fecal calprotectin was ≥75.8µg/g for distinguishing colorectal cancer from normal cases (sensitivity and specificity of 80% and 84%, respectively). This value was ≥41.9µg/g for distinguishing gastric cancer from normal cases (sensitivity and specificity of 62%). Conclusions: Our results revealed that fecal calprotectin might be a useful and non-invasive biomarker for distinguishing colorectal cancer from non-malignant GI conditions. However, due to low sensitivity and specificity, this biomarker may not help physicians distinguishing gastric cancer cases from healthy subjects.

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

“…So far it is the fourth most frequently diagnosed cancer as each year more than one million patients are annually diagnosed with gastric cancer (Ferlay et al, 2010;Hernandez et al, 2010;Basiri et al, 2014;Behnampour et al, 2014;Calik et al, 2014;Deng et al, 2014;Khoshbaten et al, 2014;Karim et al, 2014;Lu et al, 2014;Unal et al, 2014;Yang et al, 2014;Zhou et al, 2014). The incidence of stomach cancer varies geographically, with a much higher prevalence in Eastern countries than in the Western ones .…”

Periostin as a promising target of therapeutical intervention for colorectal cancer

“…Despite recent progresses in diagnosis of colorectal cancer and in its management (Dattatreya, 2013;Price et al, 2013;Khoshbaten et al, 2014), the number of mortalities is still progressively increasing every year. Many patients with localized colorectal cancer have micrometastatic disease are usually miss diagnosed, which results in disease recurrence and mortality several years after diagnosis (Noura et al, 2002).…”

Comparative Diagnostic Accuracy of Fecal Protein Biomarkers for Colorectal Advanced Neoplasms: A Systematic Review and Meta-Analysis

“…We found 23 studies with 21077 test results for FC [7][8][9]16,17,[20][21][22]27,[39][40][41][42][43][44][45][46][47][48][49][50][51][52] which all of them had the information of CRC diagnosis with 9747 test results. The results of FC for detection of AA and AN were extracted from 9 articles with 5665 test results for each condition, respectively.…”